

Additional file 4. Expression of *KDM5B* in cancer tissues analyzed by cDNA microarray*

| Tissue type | Case (n) | Ratio (Tumor / Normal) | | | |
|------------------------------------|----------|------------------------|------------|------------|----------|
| | | >2 fold | >3 fold | >5 fold | >10 fold |
| Acute myelogenous leukemia (AML) | 56 | 43 (76.8%) | 39 (69.6%) | 22 (39.3%) | 0 (0%) |
| Bladder cancer | 34 | 21 (61.8%) | 6 (17.6%) | 3 (8.8%) | 0 (0%) |
| Breast cancer | 80 | 33 (41.3%) | 11 (13.8%) | 3 (3.8%) | 0 (0%) |
| Cervical cancer | 19 | 16 (84.2%) | 13 (68.4%) | 8 (42.1%) | 1 (5.3%) |
| Chronic myelogenous leukemia (CML) | 74 | 45 (60.8%) | 24 (32.4%) | 6 (8.1%) | 2 (2.7%) |
| Non-small cell lung cancer (NSCLC) | 37 | 28 (75.7%) | 18 (48.6%) | 7 (18.9%) | 0 (0%) |
| Renal cell carcinoma (RCC) | 24 | 10 (41.7%) | 1 (4.2%) | 0 (0%) | 0 (0%) |
| Small cell lung cancer (SCLC) | 15 | 11 (73.3%) | 7 (46.7%) | 6 (40%) | 0 (0%) |

* We compared the signal intensity of *KDM5B* between tumor and corresponding non-neoplastic tissues derived from the same patient.